A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
BeOne Medicines
BeOne Medicines
Bristol-Myers Squibb
Swiss Cancer Institute
National Cancer Institute (NCI)
Janssen Research & Development, LLC
AstraZeneca
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC
Arcus Biosciences, Inc.
AstraZeneca
Taipei Veterans General Hospital, Taiwan
Boehringer Ingelheim
Wake Forest University Health Sciences
Gilead Sciences
Hoffmann-La Roche
AstraZeneca
AstraZeneca
CatalYm GmbH
Thomas Jefferson University
M.D. Anderson Cancer Center
Hackensack Meridian Health
Merck Sharp & Dohme LLC
Guangdong Association of Clinical Trials
Massachusetts General Hospital
Hoffmann-La Roche
Intergroupe Francophone de Cancerologie Thoracique
BeOne Medicines
University Hospital, Lille
Guangzhou Medical University
TJ Biopharma Co., Ltd.
Montefiore Medical Center
Tianjin Medical University Cancer Institute and Hospital
Bristol-Myers Squibb
University of Pittsburgh
Dana-Farber Cancer Institute
Beijing Cancer Prevention & Treatment Society
Regeneron Pharmaceuticals
Big Ten Cancer Research Consortium
Sun Yat-sen University
University Health Network, Toronto
Shenyang Sunshine Pharmaceutical Co., LTD.
Mario Negri Institute for Pharmacological Research
Università Vita-Salute San Raffaele
University of Utah
CSPC Megalith Biopharmaceutical Co.,Ltd.
Mayo Clinic
NRG Oncology